Cytochrome P-450 Polymorphisms and Clinical Outcome in Patients with Non-Small Cell Lung Cancer

Iscan M., ADA A. O.

TURKISH JOURNAL OF PHARMACEUTICAL SCIENCES, vol.14, no.3, pp.319-323, 2017 (ESCI) identifier identifier identifier

  • Publication Type: Article / Review
  • Volume: 14 Issue: 3
  • Publication Date: 2017
  • Doi Number: 10.4274/tjps.28291
  • Journal Indexes: Emerging Sources Citation Index (ESCI), Scopus, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.319-323
  • Keywords: CYP, polymorphisms, response to chemotherapy, survival, lung cancer, PLATINUM-BASED CHEMOTHERAPY, NSCLC PATIENTS, DOCETAXEL, SURVIVAL, ENZYMES, CYP1A1, CYP2E1
  • Ankara University Affiliated: Yes


Lung cancer is an increasing worldwide public health problem. Most patients with lung cancer have non-small cell lung cancer (NSCLC). These patients are mainly treated with standard platinum-based chemotherapy. Poor response and great inter-individual variety in treatment response occurs among these patients. There is accumulating evidence to support the hypothesis that genetic polymorphisms alter the drug response and survival. Cytochrome P450 (CYP) enzymes metabolize antineoplastic drugs and are involved in drug resistance. Polymorphic CYPs have altered enzyme activities and thus they may influence the response to chemotherapy and survival in patients with lung cancer. In the current review, recent findings with respect to the role of mainly CYP1A1, CYP1B1, CYP2D6, CYP2E1 and CYP3A4 gene polymorphisms in response to chemotherapy and survival in patients with NSCLC have been provided, which could be useful for clinicians in the prognosis of these patients who are mainly treated with platinum-based chemotherapy.